U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H13ClN2O2
Molecular Weight 300.74
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOBAZAM

SMILES

CN1C2=C(C=C(Cl)C=C2)N(C3=CC=CC=C3)C(=O)CC1=O

InChI

InChIKey=CXOXHMZGEKVPMT-UHFFFAOYSA-N
InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/clobazam.html; http://www.epilepsy.com/medications/clobazam https://www.ncbi.nlm.nih.gov/pubmed/?term=23318278

Clobazam belongs to the 1,5-benzodiazepine class of drugs with antiepileptic properties. It has been used to treat anxiety and epilepsy since 1970s. In the US clobazam was approved for marketing in October of 2011 for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. It is also approved for adjunctive therapy for epilepsy in patients who have not responded to first-line drugs and in children who are refractory to first-line drugs. The mechanism of action for clobazam is not fully understood but is thought to involve what is known as potentiation of GABAergic neurotransmission resulting from binding at a benzodiazepine site at the GABA(A) receptor. Possible side effects: constipation, fever, drowsiness, sedation, ataxia, aggressive behavior, lethargy, drooling, and irritability. Other side effects include: urinary tract infection, pneumonia, cough, dysphagia, dysarthria, bronchitis, insomnia, fatigue, decreased appetite, and increased appetite.

CNS Activity

CNS Active
3913
Curator's Comment: Has a central nervous system (CNS) depressant effect

Originator

Maestretti Research Laboratories
1
Curator's Comment: Discovery of Clobazam at the Maestretti Research Laboratories was first published in 1969. Maestretti Research Laboratories became part of Sanofi.

Approval Year

2011
587
Targets

Targets

Primary TargetPharmacologyConditionPotency
Activator
1430
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
8429
ONFI

Approved Use

Indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

Launch Date

2011
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
641 μg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6529527/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOBAZAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
13741 μg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6529527/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOBAZAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
36 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202067s005,203993s007lbl.pdf
30 mg 1 times / day unknown, oral
dose: 30 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
CLOBAZAM plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202067s005,203993s007lbl.pdf
30 mg 1 times / day unknown, oral
dose: 30 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
CLOBAZAM plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 2 times / day steady, oral
Highest studied dose
Dose: 80 mg, 2 times / day
Route: oral
Route: steady
Dose: 80 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
healthy
n = 70
Health Status: healthy
Population Size: 70
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
Disc. AE: Somnolence, Depressed mood...
Other AEs: Delirium...
AEs leading to
discontinuation/dose reduction:
Somnolence (1 patient)
Depressed mood (1 patient)
Libido decreased (1 patient)
Erectile dysfunction (1 patient)
Insomnia (1 patient)
Dysarthria (1 patient)
Unsteady gait (1 patient)
Dizziness (1 patient)
Other AEs:
Delirium (2 patients)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
healthy
n = 24
Health Status: healthy
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
Disc. AE: Transaminases increased...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
15 mg 2 times / day steady, oral
Dose: 15 mg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
healthy
n = 24
Health Status: healthy
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
Disc. AE: Transaminases increased...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
20 mg 2 times / day steady, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: steady
Dose: 20 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 70
healthy
n = 70
Health Status: healthy
Population Size: 70
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 70
Disc. AE: Transaminases increased...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (2 patients)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 70
60 mg 2 times / day steady, oral
Dose: 60 mg, 2 times / day
Route: oral
Route: steady
Dose: 60 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
healthy
n = 24
Health Status: healthy
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
Disc. AE: Somnolence...
AEs leading to
discontinuation/dose reduction:
Somnolence (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
70 mg 2 times / day steady, oral
Dose: 70 mg, 2 times / day
Route: oral
Route: steady
Dose: 70 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
healthy
n = 24
Health Status: healthy
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
Disc. AE: Dizziness, Somnolence...
AEs leading to
discontinuation/dose reduction:
Dizziness (1 patient)
Somnolence (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
AEs

AEs

AESignificanceDosePopulation
Depressed mood 1 patient
Disc. AE
80 mg 2 times / day steady, oral
Highest studied dose
Dose: 80 mg, 2 times / day
Route: oral
Route: steady
Dose: 80 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
healthy
n = 70
Health Status: healthy
Population Size: 70
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
Dizziness 1 patient
Disc. AE
80 mg 2 times / day steady, oral
Highest studied dose
Dose: 80 mg, 2 times / day
Route: oral
Route: steady
Dose: 80 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
healthy
n = 70
Health Status: healthy
Population Size: 70
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
Dysarthria 1 patient
Disc. AE
80 mg 2 times / day steady, oral
Highest studied dose
Dose: 80 mg, 2 times / day
Route: oral
Route: steady
Dose: 80 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
healthy
n = 70
Health Status: healthy
Population Size: 70
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
Erectile dysfunction 1 patient
Disc. AE
80 mg 2 times / day steady, oral
Highest studied dose
Dose: 80 mg, 2 times / day
Route: oral
Route: steady
Dose: 80 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
healthy
n = 70
Health Status: healthy
Population Size: 70
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
Insomnia 1 patient
Disc. AE
80 mg 2 times / day steady, oral
Highest studied dose
Dose: 80 mg, 2 times / day
Route: oral
Route: steady
Dose: 80 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
healthy
n = 70
Health Status: healthy
Population Size: 70
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
Libido decreased 1 patient
Disc. AE
80 mg 2 times / day steady, oral
Highest studied dose
Dose: 80 mg, 2 times / day
Route: oral
Route: steady
Dose: 80 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
healthy
n = 70
Health Status: healthy
Population Size: 70
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
Somnolence 1 patient
Disc. AE
80 mg 2 times / day steady, oral
Highest studied dose
Dose: 80 mg, 2 times / day
Route: oral
Route: steady
Dose: 80 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
healthy
n = 70
Health Status: healthy
Population Size: 70
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
Unsteady gait 1 patient
Disc. AE
80 mg 2 times / day steady, oral
Highest studied dose
Dose: 80 mg, 2 times / day
Route: oral
Route: steady
Dose: 80 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
healthy
n = 70
Health Status: healthy
Population Size: 70
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
Delirium 2 patients
80 mg 2 times / day steady, oral
Highest studied dose
Dose: 80 mg, 2 times / day
Route: oral
Route: steady
Dose: 80 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
healthy
n = 70
Health Status: healthy
Population Size: 70
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69-70
Transaminases increased 1 patient
Disc. AE
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
healthy
n = 24
Health Status: healthy
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
Transaminases increased 1 patient
Disc. AE
15 mg 2 times / day steady, oral
Dose: 15 mg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
healthy
n = 24
Health Status: healthy
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
Transaminases increased 2 patients
Disc. AE
20 mg 2 times / day steady, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: steady
Dose: 20 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 70
healthy
n = 70
Health Status: healthy
Population Size: 70
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 70
Somnolence 1 patient
Disc. AE
60 mg 2 times / day steady, oral
Dose: 60 mg, 2 times / day
Route: oral
Route: steady
Dose: 60 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
healthy
n = 24
Health Status: healthy
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
Dizziness 1 patient
Disc. AE
70 mg 2 times / day steady, oral
Dose: 70 mg, 2 times / day
Route: oral
Route: steady
Dose: 70 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
healthy
n = 24
Health Status: healthy
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
Somnolence 1 patient
Disc. AE
70 mg 2 times / day steady, oral
Dose: 70 mg, 2 times / day
Route: oral
Route: steady
Dose: 70 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
healthy
n = 24
Health Status: healthy
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf
Page: p. 69
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inducer
781

substrate
1737

inhibitor
1587
inhibitor
1767
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2C8
911

CYP2C19
1478

UGT1A1
204

UGT1A4
77

UGT1A6
108

UGT2B4
19

P-gp
1461
CYP2C19
991

CYP2B6
664

P-gp
1537

OAT
1
UGT1A1
69
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no
CYP2C19
1553
 no
CYP2C8
965
 no
CYP2C9
1819
 no
CYP3A4
1925
 no
P-gp
1650
 no
UGT1A1
254
 no
UGT1A4
80
 no
UGT1A6
141
 no
UGT2B4
19
 no
CYP2D6
1891
 no
yes (co-administration study)
Comment: clobazam increased dextromethorphan cmax 90%, auc 59%
Page: 16.0
UGT1A1
254
 weak
CYP3A4
1925
 weak
yes (co-administration study)
Comment: clobazam decreased midazolam auc 27%, cmax 24%
Page: 9.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1737
 major
yes (co-administration study)
Comment: ketoconazole increased clobazam auc 54%, no effect on cmax
Page: 15.0
CYP2B6
664
 minor
CYP2C19
991
 minor
yes (co-administration study)
Comment: omeprazole increased clobazam auc 30-36%, no effect on cmax
Page: 15.0
OAT
1
 no
P-gp
1537
 yes
yes (co-administration study)
Comment: verapamil reduced clobazam transport >96%
Page: 17.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:31413
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31413
ZINC
ZINC000000001175
http://zinc15.docking.org/substances/ZINC000000001175
eMolecules
536528
https://www.emolecules.com/cgi-bin/more?vid=536528
PubMed

PubMed

TitleDatePubMed
Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan.
2004
Therapeutic drug monitoring of old and newer anti-epileptic drugs.
2004
Development of a whole body physiologically based model to characterise the pharmacokinetics of benzodiazepines. 1: Estimation of rat tissue-plasma partition ratios.
2004 Aug
Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization.
2004 Aug
A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.
2004 Dec
In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19.
2004 Nov
Affinity of various benzodiazepine site ligands in mice with a point mutation in the GABA(A) receptor gamma2 subunit.
2004 Oct 15
Management of Landau-Kleffner syndrome.
2005
Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies.
2005
Photosensitivity in idiopathic generalized epilepsies.
2005
Levetiracetam in the treatment of infantile spasms.
2005
Stiripentol: new preparation. Severe myoclonic epilepsy of infancy: promising.
2005 Apr
A case of toxic epidermal necrolysis with lesions mostly on sun-exposed skin.
2005 Apr
[Subacute encephalitis with anti-glutamate receptor antibodies presented with epilepsia partialis continua].
2005 Aug
Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats.
2005 Dec 14
Clobazam as add-on therapy for temporal lobe epilepsy and hippocampal sclerosis.
2005 Feb
Effect of antiepileptic drug polytherapy on crystalluria.
2005 Feb
Intermittent clobazam therapy in febrile seizures.
2005 Jan
Treatment of electrical status epilepticus during slow-wave sleep with high-dose corticosteroid.
2005 Jan
[Antiepileptic drugs in the treatment of autistic regression syndromes].
2005 Jan 15
Stiripentol.
2005 Jul
Neuroembryopathic effect of clobazam in rat: a histological study.
2005 Jun
A common variable immunodeficient patient who developed acute disseminated encephalomyelitis followed by the Lennox-Gastaut syndrome.
2005 Jun
Motor impairment on awakening in a patient with an EEG pattern of "unilateral, continuous spikes and waves during slow sleep".
2005 Jun
Screening and confirmatory method for benzodiazepines and hypnotics in oral fluid by LC-MS/MS.
2005 Jun 10
Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs.
2005 May
Visually self-induced seizures sensitive to round objects.
2005 May
Screening method for benzodiazepines and hypnotics in hair at pg/mg level by liquid chromatography-mass spectrometry/mass spectrometry.
2005 Oct 15
Simultaneous determination of clobazam and its major metabolite in human plasma by a rapid HPLC method.
2005 Sep 5
Levetiracetam in idiopathic generalised epilepsy and porphyria cutanea tarda.
2006
[Epilepsy with electrical status epilepticus during slow sleep: diagnostic criteria and approaches to therapy].
2006
Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels.
2006 Apr
In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism.
2006 Apr
Landau-Kleffner syndrome is not an eponymic badge of ignorance.
2006 Aug
Effects of some antiepileptics on septal-kindled seizures in rats.
2006 Dec
[Epilepsy: which therapy in acute care?].
2006 Dec 8
Anticonvulsant hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro.
2006 Feb
Pharmacological properties of GABAA receptors containing gamma1 subunits.
2006 Feb
Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy.
2006 Jul
Safety and efficacy of clobazam versus phenytoin-sodium in the antiepileptic drug treatment of solitary cysticercus granulomas.
2006 Jun
Benign angiopathy of the central nervous system associated with phenytoin intoxication.
2006 Jun
Abusive prescription of psychostimulants: a study of two cases.
2006 Mar
Clobazam as add-on therapy in children with epileptic encephalopathy.
2006 May
Oxidative stress in children receiving valproic acid.
2006 Nov
Quantification of benzodiazepines in whole blood and serum.
2006 Nov
Treatment in the pediatric emergency department is evidence based: a retrospective analysis.
2006 Oct 6
Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy.
2006 Sep
The detection of sedatives in hair and nail samples using tandem LC-MS-MS.
2007 Feb 14
Clobazam.
2007 Jan
Stiripentol.
2007 Jan
Patents

Patents

JP2008516961A
21
US2010317715
1
US2010331312
5
US6699849
1

Sample Use Guides

In Vivo Use Guide
Patients ≤30 kg body weight: Initiate at 5 mg daily and titrate as tolerated up to 20 mg daily. Patients > 30 kg body weight: Initiate at 10 mg daily and titrate as tolerated up to 40 mg daily. For doses above 5 mg/day administer in two divided doses. Dosage adjustment needed in following groups: Geriatric patients. Known CYP2C19 poor metabolizers. Mild or moderate hepatic impairment; no information for severe hepatic impairment.
Route of Administration: Oral
In Vitro Use Guide
Recurrent ictal-like seizures (ILEs, four per hour) were generated in intact corticohippocampal formations (CHFs) of P7-8 rats, and extracellular recordings were performed in the hippocampus and neocortex. Clobazam was applied at clinically relevant concentrations (at least two), during 30 min after the third ILE. Clobazam prevented the occurrence of seizures in recurrent ictal-like seizures.
Name Type Language
CLOBAZAM
DASH   EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
CLOBAZAM [MI]
Common Name English
CLOBAZAM [JAN]
Common Name English
URBADAN
Brand Name English
1H-1,5-BENZODIAZEPINE-2,4(3H,5H)-DIONE, 7-CHLORO-1-METHYL-5-PHENYL-
Systematic Name English
CLOBAZAM [ORANGE BOOK]
Common Name English
CLOBAZAM [VANDF]
Common Name English
FRISIUM
Brand Name English
URBANYL
Brand Name English
ONFI
Brand Name English
LM 2717
Code English
LM-2717
Code English
COLBAZAM [VANDF]
Common Name English
NSC-336279
Code English
HR-376
Code English
MYSTAN
Brand Name English
H 4723
Code English
HR 376
Code English
CLOBAZAM [EP MONOGRAPH]
Common Name English
CLOBAZAM [MART.]
Common Name English
7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione
Common Name English
SYMPAZAN
Brand Name English
H-4723
Code English
clobazam [INN]
Common Name English
CLOBAZAM [USAN]
Common Name English
Clobazam [WHO-DD]
Common Name English
Classification Tree Code System Code
DEA NO. 2751
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
FDA ORPHAN DRUG 248307
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
LIVERTOX NBK548865
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
WHO-ATC N05BA09
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
NCI_THESAURUS C28197
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
WHO-VATC QN05BA09
Created by admin on Fri Dec 15 15:11:46 GMT 2023 , Edited by admin on Fri Dec 15 15:11:46 GMT 2023
NDF-RT N0000175694
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
Code System Code Type Description
CAS
22316-47-8
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
CHEBI
31413
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
WIKIPEDIA
CLOBAZAM
Created by admin on Fri Dec 15 15:11:46 GMT 2023 , Edited by admin on Fri Dec 15 15:11:46 GMT 2023
PRIMARY
MESH
C012255
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
EPA CompTox
DTXSID2046759
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
PUBCHEM
2789
Created by admin on Fri Dec 15 15:11:46 GMT 2023 , Edited by admin on Fri Dec 15 15:11:46 GMT 2023
PRIMARY
NSC
336279
Created by admin on Fri Dec 15 15:11:46 GMT 2023 , Edited by admin on Fri Dec 15 15:11:46 GMT 2023
PRIMARY
INN
3055
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
DAILYMED
2MRO291B4U
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
DRUG BANK
DB00349
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
EVMPD
SUB06673MIG
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
SMS_ID
100000084299
Created by admin on Fri Dec 15 15:11:46 GMT 2023 , Edited by admin on Fri Dec 15 15:11:46 GMT 2023
PRIMARY
ChEMBL
CHEMBL70418
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
HSDB
8343
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
FDA UNII
2MRO291B4U
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
NCI_THESAURUS
C81615
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
ECHA (EC/EINECS)
244-908-7
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
LACTMED
Clobazam
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
RXCUI
21241
Created by admin on Fri Dec 15 15:11:46 GMT 2023 , Edited by admin on Fri Dec 15 15:11:46 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m3626
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY Merck Index
NDF-RT
N0000182137
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY Cytochrome P450 2D6 Inhibitors [MoA]
IUPHAR
7149
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
DRUG CENTRAL
682
Created by admin on Fri Dec 15 15:11:45 GMT 2023 , Edited by admin on Fri Dec 15 15:11:45 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of CLOBAZAM
METABOLITE (PARENT)
Structure of 4'-HYDROXYCLOBAZAM
METABOLITE ACTIVE (PARENT)
Structure of N-Desmethylclobazam
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966